{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:49:04Z","timestamp":1782132544207,"version":"3.54.5"},"posted":{"date-parts":[[2026,6,19]]},"group-title":"Oncology","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Hyperleukocytosis (white blood cell [WBC] count &gt;100 000\/\u00b5L) at diagnosis is an important prognostic risk factor in pediatric acute lymphoblastic leukemia (ALL), though its significance with contemporary therapy is unclear. We analyzed 1 826 pediatric ALL patients from a multi-institution cohort to determine whether hyperleukocytosis independently predicts outcomes using multivariable Cox proportional hazard modeling. Hyperleukocytosis occurred in 211 patients (12%), with 121 having B-ALL, and showed no prognostic significance in T-ALL patients. In B-ALL, 5-year event-free survival (EFS) was 65% versus 89% for non-hyperleukocytosis patients, and overall survival (OS) was 78% versus 93%. After adjustment for age, cytogenetic risk, central nervous system disease status, and treatment site, hyperleukocytosis remained an independent predictor of end-of-induction minimal residual disease (MRD) positivity (odds ratio 2.53 [95% confidence interval [CI]: 1.71\u20133.94; p&lt;0.001]), inferior EFS (hazard ratio [HR] 2.44; 95% CI: 1.77\u20133.38; p&lt;0.001) and inferior OS (HR 2.00; 95% CI: 1.29\u20133.12; p=0.002). A continuous dose-response relationship was observed between WBC count and these outcomes. Survival associations persisted across all cytogenetic risk categories and MRD strata. Despite risk-adapted therapy with treatment intensification for high-risk features, hyperleukocytosis identifies an aggressive B-ALL phenotype with persistently inferior outcomes, suggesting these patients may benefit from novel therapeutic approaches.<\/jats:p>","DOI":"10.64898\/2026.06.16.26355715","type":"posted-content","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:30:15Z","timestamp":1781893815000},"source":"Crossref","is-referenced-by-count":0,"title":["Hyperleukocytosis and outcomes in pediatric B-cell acute lymphoblastic leukemia: A report from the REDIAL Consortium"],"prefix":"10.64898","author":[{"given":"Josiah J.","family":"Kim","sequence":"first","affiliation":[{"name":"Northwestern University, Evanston, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX, USA"},{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Texas Children\u2019s Cancer and Hematology Center, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Monica","family":"Gramatges","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX, USA"},{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Texas Children\u2019s Cancer and Hematology Center, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh","family":"Hoang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX, USA"},{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Texas Children\u2019s Cancer and Hematology Center, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pagna","family":"Sok","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX, USA"},{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Garcia-Morales","sequence":"additional","affiliation":[{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Children\u2019s Healthcare of Atlanta, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Huynh","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Orange County, Orange, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ludwig","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center and Children\u2019s Health, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Klesse","sequence":"additional","affiliation":[{"name":"UT Southwestern Medical Center and Children\u2019s Health, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Heym","sequence":"additional","affiliation":[{"name":"Cook Children\u2019s Medical Center, Fort Worth, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Griffin","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of San Antonio, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Erana","sequence":"additional","affiliation":[{"name":"Vannie E. Cook Children\u2019s Cancer and Hematology Clinic, McAllen, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Carlos","family":"Bernini","sequence":"additional","affiliation":[{"name":"Vannie E. Cook Children\u2019s Cancer and Hematology Clinic, McAllen, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brooke","family":"Bernhardt","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital, Memphis, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Lupo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Children\u2019s Healthcare of Atlanta, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R.","family":"Rabin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Oncology, University of California San Francisco, San Francisco CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Scheurer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Emory University School of Medicine, Children\u2019s Healthcare of Atlanta, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Zobeck","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology-Oncology, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, TX, USA"},{"name":"Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA"},{"name":"Texas Children\u2019s Cancer and Hematology Center, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026062205050502000_2026.06.16.26355715v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972"},{"issue":"27","key":"2026062205050502000_2026.06.16.26355715v1.2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration","volume":"33","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9881","key":"2026062205050502000_2026.06.16.26355715v1.3","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"2026062205050502000_2026.06.16.26355715v1.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-132837"},{"key":"2026062205050502000_2026.06.16.26355715v1.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.10.001"},{"key":"2026062205050502000_2026.06.16.26355715v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569"},{"issue":"9617","key":"2026062205050502000_2026.06.16.26355715v1.7","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","year":"2008","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"2026062205050502000_2026.06.16.26355715v1.8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/leu.2016.234","article-title":"Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy","volume":"31","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"2026062205050502000_2026.06.16.26355715v1.9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41375-024-02166-1","article-title":"Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children\u2019s Oncology Group Report","volume":"38","year":"2024","journal-title":"Leukemia"},{"issue":"22","key":"2026062205050502000_2026.06.16.26355715v1.10","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children\u2019s Oncology Group","volume":"35","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026062205050502000_2026.06.16.26355715v1.11","unstructured":"Jr FEH. rms: Regression Modeling Strategies [Internet]. 2024 [cited 2024 Nov 10]. Available from: https:\/\/cran.r-project.org\/web\/packages\/rms\/index.html"},{"key":"2026062205050502000_2026.06.16.26355715v1.12","unstructured":"Jr FEH, functions) CD (contributed several functions and maintains latex. Hmisc: Harrell Miscellaneous [Internet]. 2024 [cited 2024 Nov 10]. Available from: https:\/\/cran.r-project.org\/web\/packages\/Hmisc\/"},{"key":"2026062205050502000_2026.06.16.26355715v1.13","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2024. Available from: https:\/\/www.R-project.org\/"},{"key":"2026062205050502000_2026.06.16.26355715v1.14","doi-asserted-by":"crossref","unstructured":"Therneau TM , Grambsch PM . Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.","DOI":"10.1007\/978-1-4757-3294-8"},{"issue":"4","key":"2026062205050502000_2026.06.16.26355715v1.15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.V79.4.871.bloodjournal794871","article-title":"Complications and outcome in childhood acute lymphoblastic leukemia with hyperleukocytosis","volume":"79","year":"1992","journal-title":"Blood"},{"key":"2026062205050502000_2026.06.16.26355715v1.16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2222"},{"key":"2026062205050502000_2026.06.16.26355715v1.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4"},{"key":"2026062205050502000_2026.06.16.26355715v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.10461"},{"key":"2026062205050502000_2026.06.16.26355715v1.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-024729"},{"issue":"4","key":"2026062205050502000_2026.06.16.26355715v1.20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bjh.13160","article-title":"Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (\u2265200 \u00d7 109\/l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children\u2019s Oncology Group","volume":"168","year":"2015","journal-title":"Br J Haematol"},{"issue":"17","key":"2026062205050502000_2026.06.16.26355715v1.21","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood.2019003191","article-title":"A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia","volume":"135","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2026062205050502000_2026.06.16.26355715v1.22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V95.3.790.003k48_790_794","article-title":"Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia","volume":"95","year":"2000","journal-title":"Blood"},{"key":"2026062205050502000_2026.06.16.26355715v1.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-633685"},{"issue":"7","key":"2026062205050502000_2026.06.16.26355715v1.24","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis","volume":"3","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026062205050502000_2026.06.16.26355715v1.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252"},{"key":"2026062205050502000_2026.06.16.26355715v1.26","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0229"},{"key":"2026062205050502000_2026.06.16.26355715v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01159-z"},{"issue":"12","key":"2026062205050502000_2026.06.16.26355715v1.28","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1200\/JCO.2017.74.3617","article-title":"IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"36","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"2026062205050502000_2026.06.16.26355715v1.29","first-page":"e20190589","article-title":"Mapping and targeting of the leukemic microenvironment","volume":"217","year":"2019","journal-title":"J Exp Med"},{"issue":"21","key":"2026062205050502000_2026.06.16.26355715v1.30","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.3390\/cancers13215319","article-title":"Emerging Bone Marrow Microenvironment-Driven Mechanisms of Drug Resistance in Acute Myeloid Leukemia: Tangle or Chance?","volume":"13","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"2026062205050502000_2026.06.16.26355715v1.31","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/cancers11091253","article-title":"Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43","volume":"11","year":"2019","journal-title":"Cancers"},{"key":"2026062205050502000_2026.06.16.26355715v1.32","doi-asserted-by":"crossref","first-page":"100932","DOI":"10.1016\/j.blre.2022.100932","article-title":"Endothelial cells: major players in acute myeloid leukaemia","volume":"54","year":"2022","journal-title":"Blood Rev"},{"key":"2026062205050502000_2026.06.16.26355715v1.33","doi-asserted-by":"publisher","DOI":"10.3390\/cells9102310"},{"key":"2026062205050502000_2026.06.16.26355715v1.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511527"},{"key":"2026062205050502000_2026.06.16.26355715v1.35","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302465"},{"key":"2026062205050502000_2026.06.16.26355715v1.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.07.009"},{"key":"2026062205050502000_2026.06.16.26355715v1.37","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.htct.2023.10.003","article-title":"Clinical and prognostic significance of CD27 and CD44 expression patterns in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia","volume":"46","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"2026062205050502000_2026.06.16.26355715v1.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"2026062205050502000_2026.06.16.26355715v1.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411680"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.16.26355715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T12:05:22Z","timestamp":1782129922000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.16.26355715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":39,"URL":"https:\/\/doi.org\/10.64898\/2026.06.16.26355715","relation":{},"subject":[],"published":{"date-parts":[[2026,6,19]]},"subtype":"preprint"}}